Please assess the completion status of the following clinical trial:

Trial Title: Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CF patient 6 years~* Availability of sputum~* Signed Informed consent~Exclusion Criteria:~* Cardiac insufficiency~* Anti-inflammatory drugs on going~* Oral corticosteroid therapy~* Inhaled corticosteroids during the two weeks before inclusion,~* Patient awaiting lung transplantation~* Patient with a past history of heart/lung transplantation~* Patient with a sputum examination positive for : atypical mycobacteria, Burkholderia cepacia, Stenotrophomonas maltophilia,~* Patient chronically colonized with multiresistant Pseudomonas aeruginosa~* Orkambi© or Kalydeco© therapy~* Change of the CF treatment during the last 4 weeks +/- 2 days before inclusion : corticosteroid, pancreatic extracts, antisecretory drugs...

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- group 1 (Type: None): CF patients with Pseudomonas aeruginosa chronic colonization.
- group 2 (Type: None): CF patients without a Pseudomonas aeruginosa chronic colonization.

Based on this trial design, predict the completion outcome and termination type (if applicable).